康臣藥業(01681.HK)公佈中期業績 權益股東應占溢利4億元同比增14.9% 持續致力開拓產品市場
格隆匯8月21日丨康臣藥業(01681.HK)公佈中期業績,截至2024年6月30日止六個月,收入為人民幣12.69億元,同比增加約13.3%。公司權益股東應占溢利為人民幣4.00億元,同比增加約14.9%。每股基本及攤薄盈利分別約為人民幣0.4987元及人民幣0.4930元,擬派中期息每股0.3港元。
報吿期內,按產品系列分類,腎科系列產品銷售較去年同期錄得增長約11.1%,其中尿毒清顆粒仍然是集團的皇牌產品,維持市場領先地位;婦兒系列產品表現亮眼,銷售較去年同期增長28.7%;醫用成像對比劑銷售較去年同期增長21.1%,仍然穩佔國內磁共振成像對比劑市場的前列;骨傷系列產品銷售較去年同期增長約129.6%;皮膚系列產品銷售較去年同期下降約22.4%;肝膽系列產品銷售較去年同期下降約55.6%;其他藥物銷售較去年同期下降約46.9%。整體銷售收入的增加主要是由於集團持續致力開拓產品市場以及發展全國各地的銷售網絡所致。
於2024年上半年,集團的毛利為人民幣9.48億,與2023年同期的人民幣8.36億元相比,增加13.3%。毛利增加的原因主要是由於銷售增加。於2024年上半年,集團的平均毛利率為74.7%,與2023年同期的74.7%相比,基本持平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.